Amgen cholesterol drug cuts heart attack, stroke risk but shares fall
WASHINGTON (Reuters) - Amgen Inc's $14,000 cholesterol drug Repatha cut the risk of heart attack and stroke by over 20 percent in patients with heart disease, but results from a highly-anticipated study fell short of investor expectations and shares dropped 6 percent.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cardiology | Cholesterol | Health | Heart | Heart Attack | Heart Disease | Stroke | Study